Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02740374
Other study ID # 2014H0447
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2015
Est. completion date January 28, 2021

Study information

Verified date November 2022
Source Ohio State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the use of ROTEM, during spinal surgery is effective on diminishing the total blood loss and the risk of Allogenic Transfusion of Blood Products vs control cases without ROTEM assessment.


Description:

Study methods This is a prospective, randomized parallel-group single center study in patients undergoing elective major spine surgery. Patients will be randomized to ROTEM-guided hemostatic therapy algorithm or standard of care hemostatic therapy: arterial blood gas analysis (ABG), normalized index ratio (INR), prothrombin time (PT), thromboplastin time (aPTT), hemoglobin (Hb), platelets, and fibrinogen. Study Procedures Patients will be randomized in a 1:1 ratio to either standard of care coagulation tests (SOC) or ROTEM. No changes in surgery or anesthesia technique will be made for the purposes of the study. Standard of Care Coagulation Tests If patients are randomized to standard of care coagulation tests, these will be performed according to Ohio State University Wexner Medical Center standard practices and attending's criteria. Standard of care tests include but are not limited to: hemoglobin, platelet count, fibrinogen concentration, INR, aPTT, and PT. These will be performed at fixed time points (preoperatively, every 2 hours intraoperatively, procedure completion, and 24 hours after procedure completion). Arterial blood gases will be performed repetitively intraoperative at a fixed range every 1-hour or at attending's criteria, as well as any postoperative laboratory tests. ROTEM If patients are randomized to ROTEM, the anesthesiologist will be blinded to any intraoperative conventional coagulation test that might be performed. ROTEM will be used according to the manufacturer's instructions, using equipment and test reagents provided by Tem International GmbH. All tests will be performed at the bedside by a clinical perfusionist trained to perform ROTEM. A specific algorithm has been created and should be followed according to clinical criteria ROTEM monitoring will be performed in patients with signs of clinically relevant diffuse bleeding and in whom blood transfusion is considered (Temp >35 Celsius degrees; pH lower than 7.2; Cai above 4.6 mg/dL; Hb below 9g/dL, or below 10g/dL with anticipated greater blood loss) or at a fixed range every 2 hours or at Anesthesiologist criteria based on patient's clinical situation. Patient´s clinical situation should be consider as the most important component on the transfusion decision-making process. Packed erythrocytes will be transfused to maintain hemoglobin concentrations higher 9g/dl and higher 10g/dl in individuals with underlying cardiovascular disease or anticipated greater blood loss. Individual based dynamics strongly indicating the need for erythrocyte transfusion at anesthesiologist criteria will be also part of the transfusion making decision-making process (tachycardia, hypotension, sings of ischemia on electrocardiogram, lactic acidosis, and dynamics of bleeding). Assessment and reporting of Adverse Events The occurrence of adverse events (AE) and serious adverse events (SAE) will be recorded from the time of consent until discharge. For each AE, the relationship to the study procedures and monitoring, severity, expectedness, outcome will be determined by the PI and recorded in the study source accordingly If the case a subject withdraws from the study due to a serious adverse event the local Institutional Review Board (IRB) will be notified within 10 days.


Recruitment information / eligibility

Status Completed
Enrollment 112
Est. completion date January 28, 2021
Est. primary completion date January 28, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female age 18 years or older. 2. Able to provide inform consent or have a legal authorized representative able to sign consent on the patients behalf. 3. Female subject with a negative urine or serum pregnancy test, or not of childbearing potential, defined as surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy; or are postmenopausal for at least 1 year. 4. Patients schedule to undergo elective neurosurgery, orthopedic, or combined procedures that are expected to receive blood products intraoperatively. - Exclusion Criteria: 1. Subjects younger than 18 years old. 2. Subjects who are prisoners. 3. Subjects who refuse transfusion of blood products. 4. Females who are pregnant or breastfeeding. 5. Subjects unable to participate in the study for any reason in the opinion of the Principal Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ROTEM
ROTEM coagulation assessment and guided transfusion management.
Other:
Standard of Care
Standard Coagulation Tests assessment and guided transfusion management

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ohio State University

Outcome

Type Measure Description Time frame Safety issue
Other Cost Comparison Compare costs of ROTEM guided therapy or Standard of Care guided therapy. within 30 days after surgery
Primary Number of Participants Needing an Intraoperative Autologue Blood Product Transfusion Intraoperative Autologue Blood Product Transfusion Within surgery
Secondary Postoperative Blood Product Transfusion Fresh frozen plasma transfusion. Within postoperative 24 hours
Secondary Number of Participants Requiring Cryoprecipitate Transfusion Number of participants Perioperative- up to 24 hours after surgery start time (cumulative)
Secondary Number of Participants Requiring Platelet Transfusion Number of participants Perioperative- up to 24 hours after surgery start time (cumulative)
Secondary Fibrinogen Concentrate Transfusion Requirements Percentage Within Surgery and Postoperative 24 hours
Secondary Prothrombin Complex Transfusion Requirements Percentage Within Surgery and Postoperative 24 hours
Secondary Factor VII Transfusion Requirements Percentage Within Surgery and Postoperative 24 hours
Secondary Need for Mechanical Ventilation During Postoperative Period Within 30 days after surgery
Secondary Length of Stay on Intensive Care Unit (ICU) Within 30 days after surgery
Secondary Length of Stay on Post Anesthesia Care Unit (PACU) Within 30 days after surgery
Secondary Overall Hospital Stay Within 30 days after surgery
Secondary Surgical Site Infection within 30 days after surgery
Secondary Mortality 30 day mortality within 30 days after surgery
Secondary Cardiovascular Complications Rate within Postoperative 30 days
Secondary Thromboembolic Complications Rate within Postoperative 30 days
Secondary Respiratory Complications Rate Within postoperative 30 days
Secondary Renal System Complications Rate Within 30 postoperative days
Secondary Cerebrovascular Complications Rate within 30 postoperative days
Secondary Infectious Complications Rate Within postoperative 30 days
Secondary Reintervention Related to Postoperative Bleeding Rate Within postoperative 30 days
See also
  Status Clinical Trial Phase
Completed NCT04114253 - QStat in Liver Transplant
Recruiting NCT05077124 - Safe and Timely Antithrombotic Removal (STAR) Registry
Active, not recruiting NCT03651154 - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections N/A
Recruiting NCT04519593 - ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma N/A
Completed NCT02043132 - Tranexamic Acid in Reverse Total Shoulder Arthroplasty Phase 2/Phase 3
Withdrawn NCT00861367 - Prospective Double-blind Study for the Use of Aspirin During Transurethral Surgery of the Bladder or the Prostate N/A
Terminated NCT03246919 - Ideal Time of Oxytocin Infusion During Cesarean Section Phase 4
Completed NCT04443920 - Tranexamic Acid for Total Knee Arthroscopy Phase 4
Withdrawn NCT04933253 - Mediastinal Temperature and Post-operative Bleeding N/A
Recruiting NCT02938962 - Intravenous vs. Topical Tranexamic Acid in Revision THA (VITALITY-X) Phase 4
Recruiting NCT02130752 - Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery N/A
Recruiting NCT05164809 - Effect of Electrosurgery on Blood Loss and Intraoperative Transfusions in Musculoskeletal Tumor Surgery
Not yet recruiting NCT04574128 - Retransfusion or Not of Cardiotomy Blood N/A
Completed NCT02911831 - IV Tranexamic Acid Prior to Hysterectomy Early Phase 1
Enrolling by invitation NCT05474027 - Reducing Hypotensive Anesthesia Use With TXA During Orthognathic Surgery Phase 4
Completed NCT05391607 - Comparison Between Hyperoncotic and Isooncotic Albumin to Support Blood Loss Replacement Phase 4
Completed NCT03152461 - Evaluation of the Clinical Performance of the Quantra System With the Quantra Surgical Cartridge
Recruiting NCT02441751 - Intraoperative Volume Management and QT Interval
Completed NCT01053169 - Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study) N/A
Completed NCT00656396 - Point of Care Coagulation Testing in Patients Undergoing Major Surgery Phase 3